Australia’s Office of Drug Control has issued medical cannabis research licenses to two firms allowing them to cultivate and manufacture products for medical studies. The licenses were awarded to Canndeo LTD., a wholly-owned subsidiary of The Hydroponics Company (THC); and to a partnership between AusCann and Tasmanian Alkaloids.
According to a report from the Examiner, Tasmanian Alkaloids currently produces about 40 percent of the world’s opiate crop.
Primary Industries Minister Jeremy Rockliff called the license a “significant step” toward the cultivation of medical cannabis in Tasmania.
“This is a major milestone for the strategic partnership and represents significant progress in our joint strategy to become a leading producer and supplier of high quality medicinal cannabis to Australian patients,” said AusCann managing director Elaine Darby in the Examiner report.
Dr. Andrew Beehag, Canndeo CEO, said the license “effectively paves the way forward for future domestic